221 related articles for article (PubMed ID: 15001972)
21. Polymorphisms in factor II and factor VII genes modulate oral anticoagulation with warfarin.
D'Ambrosio RL; D'Andrea G; Cappucci F; Chetta M; Di Perna P; Brancaccio V; Grandone E; Margaglione M
Haematologica; 2004 Dec; 89(12):1510-6. PubMed ID: 15590403
[TBL] [Abstract][Full Text] [Related]
22. Limited sampling strategy of S-warfarin concentrations, but not warfarin S/R ratios, accurately predicts S-warfarin AUC during baseline and inhibition in CYP2C9 extensive metabolizers.
Ma JD; Nafziger AN; Kashuba AD; Kim MJ; Gaedigk A; Rowland E; Kim JS; Bertino JS
J Clin Pharmacol; 2004 Jun; 44(6):570-6. PubMed ID: 15145963
[TBL] [Abstract][Full Text] [Related]
23. The influence of (R)- and (S)-warfarin, vitamin K and vitamin K epoxide upon warfarin anticoagulation.
Kamali F; Edwards C; Butler TJ; Wynne HA
Thromb Haemost; 2000 Jul; 84(1):39-42. PubMed ID: 10928467
[TBL] [Abstract][Full Text] [Related]
24. Oral anticoagulation with warfarin is significantly influenced by steroids and CYP2C9 polymorphisms in children with cancer.
Ruud E; Holmstrøm H; Bergan S; Wesenberg F
Pediatr Blood Cancer; 2008 Mar; 50(3):710-3. PubMed ID: 17226852
[TBL] [Abstract][Full Text] [Related]
25. [Significance of cytochrome P450 2C9 genotype for the bleeding complications in patients treated with acenocoumarol].
Márk L; Márki-Zay J; Fodor L; Kondacs A; Paragh G; Katona A
Orv Hetil; 2005 Apr; 146(16):739-43. PubMed ID: 15889670
[TBL] [Abstract][Full Text] [Related]
26. Frequency of CYP2C9 polymorphisms affecting warfarin metabolism in a large anticoagulant clinic cohort.
Moridani M; Fu L; Selby R; Yun F; Sukovic T; Wong B; Cole DE
Clin Biochem; 2006 Jun; 39(6):606-12. PubMed ID: 16630605
[TBL] [Abstract][Full Text] [Related]
27. [Genetic and bioenvironmental factors associated with warfarin response in Colombian patients].
Isaza C; Beltrán L; Henao J; Porras G; Pinzón A; Vallejos A; Machado J
Biomedica; 2010; 30(3):410-20. PubMed ID: 21713343
[TBL] [Abstract][Full Text] [Related]
28. Search for predictors of nontherapeutic INR results with warfarin therapy.
McGriff-Lee NJ; Csako G; Chen JT; Dang DK; Rosenfeld KG; Cannon RO; Macklin LR; Wesley RA;
Ann Pharmacother; 2005 Dec; 39(12):1996-2002. PubMed ID: 16288081
[TBL] [Abstract][Full Text] [Related]
29. Low dose requirement for warfarin treatment in a patient with CYP2C9*3/*13 genotype.
Kwon MJ; On YK; Huh W; Ko JW; Kim DK; Kim JS; Lee SY
Clin Chim Acta; 2011 Nov; 412(23-24):2343-5. PubMed ID: 21782804
[TBL] [Abstract][Full Text] [Related]
30. Warfarin dosing and cytochrome P450 2C9 polymorphisms.
Joffe HV; Xu R; Johnson FB; Longtine J; Kucher N; Goldhaber SZ
Thromb Haemost; 2004 Jun; 91(6):1123-8. PubMed ID: 15175798
[TBL] [Abstract][Full Text] [Related]
31. Warfarin metabolism and anticoagulant effect: a prospective, observational study of the impact of CYP2C9 genetic polymorphism in the presence of drug-disease and drug-drug interactions.
Muszkat M; Blotnik S; Elami A; Krasilnikov I; Caraco Y
Clin Ther; 2007 Mar; 29(3):427-37. PubMed ID: 17577464
[TBL] [Abstract][Full Text] [Related]
32. Association between the CYP2C9 polymorphism and the drug metabolism phenotype.
Topić E; Stefanović M; Samardzija M
Clin Chem Lab Med; 2004 Jan; 42(1):72-8. PubMed ID: 15061384
[TBL] [Abstract][Full Text] [Related]
33. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.
Aithal GP; Day CP; Kesteven PJ; Daly AK
Lancet; 1999 Feb; 353(9154):717-9. PubMed ID: 10073515
[TBL] [Abstract][Full Text] [Related]
34. Genetic modulation of oral anticoagulation with warfarin.
Margaglione M; Colaizzo D; D'Andrea G; Brancaccio V; Ciampa A; Grandone E; Di Minno G
Thromb Haemost; 2000 Nov; 84(5):775-8. PubMed ID: 11127854
[TBL] [Abstract][Full Text] [Related]
35. Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors.
Wadelius M; Sörlin K; Wallerman O; Karlsson J; Yue QY; Magnusson PK; Wadelius C; Melhus H
Pharmacogenomics J; 2004; 4(1):40-8. PubMed ID: 14676821
[TBL] [Abstract][Full Text] [Related]
36. Acenocoumarol pharmacokinetics in relation to cytochrome P450 2C9 genotype.
Thijssen HH; Ritzen B
Clin Pharmacol Ther; 2003 Jul; 74(1):61-8. PubMed ID: 12844136
[TBL] [Abstract][Full Text] [Related]
37. Warfarin dose adjustments based on CYP2C9 genetic polymorphisms.
Linder MW; Looney S; Adams JE; Johnson N; Antonino-Green D; Lacefield N; Bukaveckas BL; Valdes R
J Thromb Thrombolysis; 2002 Dec; 14(3):227-32. PubMed ID: 12913403
[TBL] [Abstract][Full Text] [Related]
38. Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients.
Takahashi H; Wilkinson GR; Caraco Y; Muszkat M; Kim RB; Kashima T; Kimura S; Echizen H
Clin Pharmacol Ther; 2003 Mar; 73(3):253-63. PubMed ID: 12621390
[TBL] [Abstract][Full Text] [Related]
39. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance.
Scordo MG; Pengo V; Spina E; Dahl ML; Gusella M; Padrini R
Clin Pharmacol Ther; 2002 Dec; 72(6):702-10. PubMed ID: 12496751
[TBL] [Abstract][Full Text] [Related]
40. Potentiation of anticoagulant effect of warfarin caused by enantioselective metabolic inhibition by the uricosuric agent benzbromarone.
Takahashi H; Sato T; Shimoyama Y; Shioda N; Shimizu T; Kubo S; Tamura N; Tainaka H; Yasumori T; Echizen H
Clin Pharmacol Ther; 1999 Dec; 66(6):569-81. PubMed ID: 10613612
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
